Vertex Pharmaceuticals Incorporated
Stock Forecast, Prediction & Price Target
Vertex Pharmaceuticals Incorporated (VRTX) stock Price Target by analysts
Vertex Pharmaceuticals Incorporated (VRTX) stock Price Target by analysts
Average Price Target
$495.14
Potential upside: 26.79%
Vertex Pharmaceuticals Incorporated price prediction
What is Vertex Pharmaceuticals Incorporated stock analysts` prediction?
Vertex Pharmaceuticals Incorporated stock forecast: Based on 6 Wall Street analysts` predicted price targets for Vertex Pharmaceuticals Incorporated in the last 3 months, the avarage price target is $495.14, with a high forecast of $NaN. The average price target represents a 26.79% change from the last price of $390.5.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Vertex Pharmaceuticals Incorporated stock Price Target by analysts
Full breakdown of analysts given Vertex Pharmaceuticals Incorporated price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Brian Abrahams RBC Capital | 0% 0/5 | 10 months ago | $400 2.43% upside | $469.22 | TheFly | Previous targets (4) |
Michael Yee Jefferies | 50% 1/2 | 10 months ago | $550 40.84% upside | $462.1 | StreetInsider | Previous targets (1) |
Hartaj Singh Oppenheimer | 33.33% 1/3 | 12 months ago | $540 38.28% upside | $499.1 | StreetInsider | Previous targets (2) |
Brian Abrahams RBC Capital | 0% 0/5 | 12 months ago | $451 15.49% upside | $499.88 | StreetInsider | Previous targets (4) |
Whitney Ijem Canaccord Genuity | 0% 0/1 | 12 months ago | $361 -7.55% downside | $478.09 | StreetInsider | Previous targets (0) |
Salveen Richter Goldman Sachs | 0% 0/1 | 12 months ago | $598 53.13% upside | $483 | StreetInsider | Previous targets (0) |
Evan David Seigerman BMO Capital | 0% 0/2 | 12 months ago | $566 44.94% upside | $485.74 | StreetInsider | Previous targets (1) |
Geoff Meacham Bank of America Securities | 50% 1/2 | about 1 year ago | $541 38.54% upside | $482.12 | TheFly | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/5 | about 1 year ago | $437 11.90% upside | $458.94 | TheFly | Previous targets (4) |
Hartaj Singh Oppenheimer | 33.33% 1/3 | about 1 year ago | $550 40.84% upside | $477.86 | StreetInsider | Previous targets (2) |
Andy Chen Wolfe Research | 0% 0/1 | about 1 year ago | $576 47.50% upside | $476.91 | StreetInsider | Previous targets (0) |
Joon Lee Truist Financial | 0% 0/1 | about 1 year ago | $550 40.84% upside | $494.46 | TheFly | Previous targets (0) |
Andrew Fein H.C. Wainwright | 0% 0/2 | about 1 year ago | $600 53.64% upside | $505.78 | TheFly | Previous targets (1) |
Jasper Hellweg Argus Research | 50% 1/2 | over 1 year ago | $550 40.84% upside | $474.61 | TheFly | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/5 | over 1 year ago | $421 7.81% upside | $483.28 | StreetInsider | Previous targets (4) |
Evan David Seigerman BMO Capital | 0% 0/2 | over 1 year ago | $500 28.04% upside | $443.05 | StreetInsider | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/5 | over 1 year ago | $424 8.57% upside | $402.5 | StreetInsider | Previous targets (4) |
Christopher Raymond Raymond James | 0% 0/1 | over 1 year ago | $456 16.77% upside | $413.42 | StreetInsider | Previous targets (0) |
Liisa Bayko Evercore ISI | 0% 0/1 | over 1 year ago | $438 12.16% upside | $397.58 | StreetInsider | Previous targets (0) |
Andrew Fein H.C. Wainwright | 0% 0/2 | over 1 year ago | $462 18.30% upside | $397.58 | TheFly | Previous targets (1) |
Unknown H.C. Wainwright | N/A | over 2 years ago | $326 -16.51% downside | $308.54 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 2 years ago | $365 -6.53% downside | $308.54 | Benzinga | N/A |
Unknown Argus Research | N/A | almost 3 years ago | $340 -12.93% downside | $310.86 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | about 3 years ago | $253 -35.21% downside | $290.68 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | about 3 years ago | $300 -23.17% downside | $279.54 | Benzinga | N/A |
Olivia Brayer Cantor Fitzgerald | 100% 1/1 | over 3 years ago | $365 -6.53% downside | $290.01 | TheFly | Previous targets (0) |
Paul Matteis Stifel Nicolaus | 100% 1/1 | over 3 years ago | $240 -38.54% downside | $295.46 | TheFly | Previous targets (0) |
Jasper Hellweg Argus Research | 50% 1/2 | over 3 years ago | $280 -28.29% downside | $287.32 | Pulse 2.0 | Previous targets (1) |
Matthew Harrison Morgan Stanley | 100% 2/2 | over 3 years ago | $250 -35.97% downside | $261.96 | TheFly | Previous targets (1) |
Hartaj Singh Oppenheimer | 33.33% 1/3 | over 3 years ago | $350 -10.37% downside | $272.39 | Pulse 2.0 | Previous targets (2) |
Brian Skorney Robert W. Baird | 100% 1/1 | over 3 years ago | $240 -38.54% downside | $251.88 | TipRanks Contributor | Previous targets (0) |
Evan Seigerman BMO Capital | 100% 1/1 | over 3 years ago | $274 -29.83% downside | $251.88 | StreetInsider | Previous targets (0) |
Cory Kasimov J.P. Morgan | 100% 1/1 | over 3 years ago | $288 -26.24% downside | $228.22 | StreetInsider | Previous targets (0) |
Matthew Harrison Morgan Stanley | 100% 2/2 | over 3 years ago | $208 -46.73% downside | $228.22 | StreetInsider | Previous targets (1) |
Andrew Galler Wolfe Research | 100% 1/1 | over 3 years ago | $282 -27.78% downside | $228.22 | StreetInsider | Previous targets (0) |
Michael Yee Jefferies | 50% 1/2 | over 3 years ago | $275 -29.57% downside | $228.22 | TheFly | Previous targets (1) |
Phil Nadeau Cowen & Co. | 100% 1/1 | over 3 years ago | $300 -23.17% downside | $229.68 | StreetInsider | Previous targets (0) |
Geoff Porges Leerink Partners | 100% 1/1 | almost 4 years ago | $175 -55.18% downside | $204.45 | TipRanks | Previous targets (0) |
Debjit Chattopadhyay Guggenheim | 100% 1/1 | almost 4 years ago | $286 -26.76% downside | $205 | StreetInsider | Previous targets (0) |
Geoff Meacham Bank of America Securities | 50% 1/2 | almost 4 years ago | $275 -29.57% downside | $181.4 | Investing | Previous targets (1) |
Gena Wang Barclays | 100% 1/1 | over 4 years ago | $285 -27.01% downside | $193.02 | TheFly | Previous targets (0) |
Alethia Young Cantor Fitzgerald | 100% 1/1 | over 4 years ago | $281 -28.04% downside | $193.02 | TheFly | Previous targets (0) |
Colin Bristow UBS | 100% 1/1 | over 4 years ago | $279 -28.55% downside | $212.68 | StreetInsider | Previous targets (0) |
Vertex Pharmaceuticals Incorporated Financial Estimates
Vertex Pharmaceuticals Incorporated Revenue Estimates
Vertex Pharmaceuticals Incorporated EBITDA Estimates
Vertex Pharmaceuticals Incorporated Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $7.57B N/A | $8.93B 17.90% | $9.86B 10.50% | Avg: $11.67B Low: $11.25B High: $13.22B avg. 18.33% | Avg: $12.86B Low: $12.47B High: $13.81B avg. 10.16% | Avg: $14.01B Low: $13.58B High: $15.04B avg. 8.94% | Avg: $15.16B Low: $14.70B High: $16.27B avg. 8.18% |
Net Income
% change YoY
| $2.34B N/A | $3.32B 41.83% | $3.61B 8.95% | Avg: $4.45B Low: $3.58B High: $5.60B avg. 23.21% | Avg: $5.09B Low: $4.05B High: $6.46B avg. 14.22% | Avg: $5.87B Low: $5.64B High: $6.44B avg. 15.39% | Avg: $6.47B Low: $6.22B High: $7.09B avg. 10.19% |
EBITDA
% change YoY
| $2.78B N/A | $4.34B 55.80% | $4.60B 5.98% | Avg: $4.94B Low: $4.76B High: $5.60B avg. 7.43% | Avg: $5.45B Low: $5.28B High: $5.85B avg. 10.16% | Avg: $5.93B Low: $5.75B High: $6.37B avg. 8.94% | Avg: $6.42B Low: $6.22B High: $6.89B avg. 8.18% |
EPS
% change YoY
| $9.09 N/A | $12.97 42.68% | $14.05 8.32% | Avg: $16.89 Low: $13.78 High: $21.53 avg. 20.18% | Avg: $19.26 Low: $15.56 High: $24.83 avg. 14.03% | Avg: $22.57 Low: $21.67 High: $24.72 avg. 17.19% | Avg: $24.87 Low: $23.88 High: $27.24 avg. 10.19% |
Operating Expenses
% change YoY
| $3.89B N/A | $3.48B -10.43% | $4.77B 37.01% | Avg: $1.43B Low: $1.38B High: $1.62B avg. -69.93% | Avg: $1.58B Low: $1.53B High: $1.69B avg. 10.16% | Avg: $1.72B Low: $1.67B High: $1.84B avg. 8.94% | Avg: $1.86B Low: $1.80B High: $2.00B avg. 8.18% |
FAQ
What is Vertex Pharmaceuticals Incorporated stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 15.75% in 2025-2028.
We have gathered data from 18 analysts. Their low estimate is 3.58B, average is 4.45B and high is 5.60B.
What is Vertex Pharmaceuticals Incorporated stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 11.40% in 2025-2028.
We have gathered data from 24 analysts. Their low revenue estimate is $11.25B, average is $11.67B and high is $13.22B.
What is Vertex Pharmaceuticals Incorporated stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.39% in 2025-2028.
We have gathered data from 18 analysts. Their low earnings per share estimate is $13.78, average is $16.89 and high is $21.53.
What is the best performing analyst?
In the last twelve months 6 analysts have been covering Vertex Pharmaceuticals Incorporated stock. The most successful analyst is Brian Abrahams.